AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05582954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EsteemUp
Description: EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.
Study NCT05582954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EsteemUp-G
Description: The gamification elements added to this arm include (1) Badges - digital rewards upon completing important milestones within the programme EsteemUp. (2) Unlockable content - downloadable worksheets of the exercises that they have done in the module, (3) A certification of completion at the end of the program, (4) Goal setting (5) Gamification terminology - All homework assignments will be framed as a 'challenge' that needs to be completed, (6) a progress bar that will indicate how far along the participant is in the program
Study NCT05201456 — intervention group
Intervention type: DEVICE
Intervention: LithoVue Elite System
Description: The LithoVue Elite System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
Study NCT04482023 — intervention group
Intervention type: BEHAVIORAL
Intervention: Training video on anxiety, fear and loneliness in the COVID-19 environment.
Description: Video with the actions identified as essential to address the diagnosis of anxiety, fear and loneliness in the environment COVID-19 identified by a group of experts.
Study NCT04853875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline, Metronidazole, Bismuth subcitrate
Description: 52 participants (Group A) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Tetracycline, Metronidazole, and Bismuth subcitrate
Study NCT04853875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin, Metronidazole, Clarithromycin
Description: 52 participants (Group B) are randomly assigned to receive intraluminal eradication of H. pylori with medicament containing Amoxicillin, Metronidazole, and Clarithromycin
Study NCT05112120 — intervention group
Intervention type: DRUG
Intervention: Olumiant
Description: Olumiant (4mg) will be administered in line with standard of care guidance.
Study NCT05866250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler-based renal resistive index
Description: The kidney's interlobular or arcuate artery was preferentially selected and measured by pulse-wave Doppler.
Study NCT06255847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide, cyclophosphamide combined with dexametha
Description: The starting dose of pomalidomide was 2 mg in all cases，the starting dose of cyclophosphamide was 50 mg/day.If the adverse event is attributable to a specific study drug, the dose is reduced accordingly for that drug; if the adverse event is associated with multiple drugs, the dose is reduced appropriately for one of the predominantly associated drugs at the discretion of the investigator; and if multiple adverse events occur concurrently, the dose should be adjusted according to the guidelines for the most severe toxicity.
Study NCT05752422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niraxx G1 Headband Device including sham
Description: Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
Study NCT05752422 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Niraxx G1 Headband Device including sham
Description: Exploring effect of active t-PBM delivered by Niraxx G1 Headband versus sham condition
Study NCT05059353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digitally based multidomain intervention
Description: Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed.
Study NCT05399771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler
Description: Study team will use a PeriScan PIM 3 System Laser Doppler to scan for blood perfusion before and after the Thermofield treatment. The PeriScan PIM 3 System is for non-invasive two-dimensional imaging of peripheral tissue.
Study NCT05399771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Heating System
Description: The radiofrequency will be set to achieve 42°C/107.6°F) and maintain this temperature consistently during the application time. This temperature is mild and may feel like a drugstore heating pad. The device will be turned on on one leg and will remain off on the other. The time for the heating will be 36 minutes, during which participants will remain in a reclined position, with their legs elevated. The device takes approximately 6 minutes to achieve a tissue temperature of 42°C, and the treatment time with consistent temperature application will be 30 minutes.
Study NCT04840030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (MM-int)
Description: 1. Cognitive intervention objective: To enhance cognitive functioning and incorporate daily habits and routines that are cognitively stimulating~2. Socio-emotional intervention objective: • Promote socio-emotional skills associated with awareness, communication and regulation of emotions in late life.~3. Nutritional intervention objective: To improve eating habits of participants to be based on the Mediterranean Dietary pattern by an educational program~4. Physical activity intervention objective: To improve aerobic capacity y, decrease the risk of falls, and improve static and dynamic balance.~5. Risk factors and comorbidities monitoring intervention: quarterly scheduled visits for a cardiovascular risk factors check-up and review active medication
Study NCT05576974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegsitacianine
Description: Infusion of the Pegsitacianine-Intraoperative fluorescence imaging
Study NCT05795478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone and Pregabalin
Description: Oxycodone: 150mg PCIA during 3 days postoperatively Pregabalin: 150mg preoperatvely, 75mg BID for POD1\~7,75mg QD for POD8\~14
Study NCT05795478 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone and placebo capsules
Description: Oxycodone: 150mg PCIA for 3 days postoperatively placebo capsules: same numbers as pregabalin at each time point
Study NCT05795478 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin and NS
Description: Pregabalin: 150mg preoperatively, 75mg BID for POD1\~7,75mg QD for POD8\~14 NS: Equal volume NS for 3 days postoperatively
Study NCT05795478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules and NS
Description: placebo capsules: same numbers as pregabalin at each time point NS: Equal volume NS for 3 days postoperatively
Study NCT05146453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectointercostal fascia blocks
Description: PIF blocks will be placed at the conclusion of surgery with the surgical drapes in place. The blocks are performed using a high frequency linear transducer with aseptic technique. The ultrasound probe is placed longitudinally 3 cm from the sternum at the level of the 4th-6th intercostal space. Using an in-plane approach, an echogenic needle will be advanced into the fascial plane between pectoralis major and the external intercostal muscles. Peripheral nerve block catheters will then be inserted and secured to the skin surface with tegaderm. For patients weighing over 70 kg, 20 mL of 0.5% ropivacaine will be administered. This will be reduced to 15mL per side for patients weighing less than 70 kg. A CADD™ pump will be connected to each catheter and programmed to deliver 20 mL boluses of ropivacaine 0.2% starting at postoperative hour 2. The boluses will be staggered every 2 hours on alternate sides until hour 24. The catheters will be removed 24 hours post-operatively.
Study NCT05146453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
Study NCT05291468 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET/CT
Description: Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
Study NCT05291468 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: FDG-PET/CT
Description: Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.
Study NCT06255366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caroxime sodium sulfonate
Description: Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
Study NCT06255366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
Study NCT06255366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
Study NCT05098275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/500mg
Description: single dose administration (one tablet once a day)
Study NCT05098275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/500mg
Description: single dose administration (one tablet once a day)
Study NCT06408155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric Task
Description: The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
Study NCT06408155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Task
Description: The task demanded that participants maintain their arm bent at a 90° angle while holding a dumbbell, which weighed 80% of their one-repetition maximum (1RM), in a supine grip on the dominant side of their body for the longest time they could.
Study NCT05449470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDSS
Description: A clinical decision support system (CDSS) that provides deprescribing advice and a personalized risk prediction
Study NCT05449470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Portal
Description: A Patient Portal that helps patients prepare for their fall clinic visit by giving them information about falls, falls prevention, and medication-related falls. After the fall clinic visit, the Patient Portal also shows the personalized fall-risk and treatment advice.
Study NCT04804215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraductal transanastomotic stent group
Description: When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
Study NCT04804215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No stent group
Description: Do not insert a stent into the bile duct during anastomosis of the bile duct.
Study NCT05399771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Imaging
Description: Study team will take thermal imaging photographs of the treatment area following each treatment.
Study NCT05399771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthcare Questionnaire & Measurement
Description: A survey tool created to collect info from participants including:~1. Name~2. Age~3. Weight/ height~4. Pregnant or nursing?~5. History of blood clots?~6. Any wound healing problems?~7. Any active open wounds on the legs?~8. Any autoimmune disorders?~9. Phone number~10. Email address~A measurement of the participants calf will be taken as well using a measuring tape.
Study NCT06488391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using a Portable Visualized Device for Self-Directed Breathing Training
Description: Using a Portable Visualized Device for Self-Directed Breathing Training
Study NCT06022718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: Kinesio taping and Rigid taping was applied.
Study NCT04926415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 30 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
Study NCT04926415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham taVNS
Description: A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
Study NCT03994159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the PARO emotional robot
Description: PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
Study NCT05834855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Treatment with rituximab
Study NCT04307875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure measurement (sphygmomanometer)
Description: measuring blood pressure with standard sphygmomanometer
Study NCT04307875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood glucose measurement
Description: measuring blood glucose using standard measurement devices
Study NCT04307875 — intervention group
Intervention type: OTHER
Intervention: psychometric tests
Description: WHODAS 2.0, PHQ-9, CAPS-5
Study NCT05166239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
Study NCT05166239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 1
Description: 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.
Study NCT05166239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
Study NCT05166239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib 2
Description: 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.
Study NCT05166239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 inhibitors 2
Description: PD-1 inhibitors injection intravenously or percutaneously every 4 week.
Study NCT04698850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 40 MG/ML [Eylea]
Description: Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
Study NCT04698850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab-Dbll 120 MG/ML [Beovu]
Description: Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
Study NCT04698850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 6 MG/ML [Lucentis]
Description: Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
Study NCT04698850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 6 MG/ML [Lucentis]
Description: Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
Study NCT06142890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cooling (control)
Description: Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.
Study NCT06142890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling with ceiling fan
Description: Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
Study NCT05638321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIMS
Description: sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
Study NCT05653895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol
Study NCT05653895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin
Study NCT05653895 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-Carnitin, L Arginine, Co-Q10
Description: Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
Study NCT06475716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based guided programme Spring
Description: Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.
Study NCT06475716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based guided programme Spring
Description: Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.